Search

Your search keyword '"Switchenko, Jeffrey M."' showing total 851 results
Start Over Author "Switchenko, Jeffrey M."
851 results on '"Switchenko, Jeffrey M."'

2. Pre-operative stereotactic radiosurgery and peri-operative dexamethasone for resectable brain metastases: a two-arm pilot study evaluating clinical outcomes and immunological correlates

Author

Jansen, Caroline S., Pagadala, Meghana S., Cardenas, Maria A., Prabhu, Roshan S., Goyal, Subir, Zhou, Chengjing, Chappa, Prasanthi, Vo, BaoHan T., Ye, Chengyu, Hopkins, Benjamin, Zhong, Jim, Klie, Adam, Daniels, Taylor, Admassu, Maedot, Green, India, Pfister, Neil T., Neill, Stewart G., Switchenko, Jeffrey M., Prokhnevska, Nataliya, Hoang, Kimberly B., Torres, Mylin A., Logan, Suzanna, Olson, Jeffrey J., Nduom, Edjah K., del Balzo, Luke, Patel, Kirtesh, Burri, Stuart H., Asher, Anthony L., Wilkinson, Scott, Lake, Ross, Kesarwala, Aparna H., Higgins, Kristin A., Patel, Pretesh, Dhere, Vishal, Sowalsky, Adam G., Carter, Hannah, Khan, Mohammad K., Kissick, Haydn, and Buchwald, Zachary S.

Published
2024
Full Text
View/download PDF

8. Early Relapse Identifies MCL patients with Inferior Survival after Intensive or Less Intensive Frontline Therapy

Author

Bond, David A, Switchenko, Jeffrey M, Villa, Diego, Maddocks, Kami, Churnetski, Michael C, Gerrie, Alina S, Goyal, Subir, Shanmugasundaram, Krithika, Calzada, Oscar, Kolla, Bhaskar, Bachanova, Veronika, Gerson, James Nathan, Barta, Stefan K, Hill, Brian T, Sawalha, Yazeed, Martin, Peter, Maldonado, Edward, Gordon, Max J, Danilov, Alexey V, Grover, Natalie Sophia, Mathews, Stephanie P, Burkart, Madelyn, Karmali, Reem, Ghosh, Nilanjan, Park, Steven I, Epperla, Narendranath, Badar, Talha, Guo, Jin, Hamadani, Mehdi, Fenske, Timothy S, Malecek, Mary-Kate, Kahl, Brad S, Flowers, Christopher R, Blum, Kristie, and Cohen, Jonathon B

Subjects
Rare Diseases, Prevention, Hematology, Lymphoma, Cancer, Adult, Humans, Lymphoma, Mantle-Cell, Prognosis, Prospective Studies, Recurrence, Treatment Outcome
Abstract

Although an expanding array of effective treatments has resulted in recent improvement in survival of patients with mantle cell lymphoma (MCL), outcomes remain heterogeneous, and identification of prognostic factors remains a priority. We assessed the prognostic impact of time to progression of disease (POD) after first-line therapy among 455 patients with relapsed MCL. Patients were categorized by duration of first remission as PRF/POD6, defined as progressive disease during induction or POD within 6 months of diagnosis (n = 65; 14%); POD6-24, defined as POD between 6 and 24 months after diagnosis (n = 153; 34%); and POD>24, defined as POD >24 months after diagnosis (n = 237; 53%). The median overall survival from POD (OS2) was 1.3 years (95% confidence interval [CI], 0.9-2.4) for patients with PRF/POD6, 3 years (95% CI, 2-6.8) for those with POD6-24, and 8 years (95% CI, 6.2-NR) for those with POD>24. Median OS2 was inferior in patients with early POD (defined as PRF/POD6 or POD6-24) after both intensive and less intensive frontline treatment. The prognostic performance of time until POD was replicated in an independent cohort of 245 patients with relapsed MCL, with median OS2 of 0.3 years (95% CI, 0.1-0.5) for PRF/POD6, 0.8 years (95% CI, 0.6-0.9) for POD6-24, and 2.4 years (95% CI 2.1-2.7) for POD>24. Early POD is associated with inferior OS2 in patients with relapsed MCL, identifying a high-risk population for future prospective studies.

Published
2021

11. A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma

Author

Sawalha, Yazeed, Goyal, Subir, Switchenko, Jeffrey M., Romancik, Jason T., Kamdar, Manali, Greenwell, I. Brian, Hess, Brian T., Isaac, Krista M., Portell, Craig A., Mejia Garcia, Alex, Goldsmith, Scott, Grover, Natalie S., Riedell, Peter A., Karmali, Reem, Burkart, Madelyn, Buege, Michael, Akhtar, Othman, Torka, Pallawi, Kumar, Anita, Hill, Brian T., Kahl, Brad S., and Cohen, Jonathon B.

Published
2023
Full Text
View/download PDF

13. Risk Stratification of Prostatic Adenocarcinoma Metastatic to the Lymph Nodes

Author

Bidot, Samuel, Monsrud, Ashley, Kline, Meredith, Speak, Alexandra, Martini, Dylan, Bilen, Mehmet A., Switchenko, Jeffrey M., Zhang, Yuzi, Gerges, Amany Ghaly, Farhat, Ghada N., Dent, Edward A., Master, Viraj A., Tinsley, Mazie L., and Harik, Lara R.

Subjects
Prostate cancer -- Prognosis, Adenocarcinoma -- Prognosis, Lymphatic metastasis -- Prognosis, Tumor staging -- Methods, Cancer -- Relapse, Health
Abstract

* Context.--The pathologic nodal staging of prostatic adenocarcinoma is binary for regional lymph nodes. Stages pN0 and pN1 indicate the absence or presence of regional nodal metastasis, respectively, whereas patients with metastasis to nonregional lymph nodes are staged as pM1a. Objective.--To determine the risk of recurrence of pN1 prostatic adenocarcinoma patients based on the extent of nodal tumor burden. Design.--We retrospectively reviewed pN1 patients with prostatic adenocarcinoma managed with radical prostatectomy seen between 2011 and 2019. Kaplan-Meier and Cox regression analyses were performed to compare disease-free survival. Results.--Ninety-six patients were included (median [interquartile range] age, 62 years [57-67 years]; 70 of 96 [73%] White). On univariate analysis, age .65 years (P = .008), [greater than or equal to] 2 positive regional lymph nodes (P < .001), and a maximum size of the tumor deposit [greater than or equal to] 2 mm (P = .004) were significantly associated with an unfavorable outcome. Controlling for age, stage, metastatic deposit size, margin status, and the presence of extranodal extension, patients with [greater than or equal to] 2 positive regional lymph nodes were 3.03 times more likely (95% confidence interval, 1.39-6.60; P = .005) to have an unfavorable outcome. Patients with pN1M1a stage showed a disease-free survival similar to that of pN1M0 patients, after controlling for the number of positive regional lymph nodes (P = .36). Conclusions.--Overall, pN1 patients with [greater than or equal to] 2 positive regional lymph nodes are 3 times more likely to have an unfavorable outcome. The results suggest a benefit in further stratifying patients with metastatic prostatic adenocarcinoma to the lymph nodes into prognostically significant risk categories that could help the treating clinicians tailor subsequent patient follow-up and therapy. doi: 10.5858/arpa.2021-0247-OA, Prostate cancer is the third most common cancer in the United States, with 191 930 new cases and 33 330 deaths occurring every year. Approximately 1 in 9 men develops [...]

Published
2022
Full Text
View/download PDF

23. Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey

Author

Harkins, R. Andrew, Patel, Sharvil P., Lee, Michelle J., Switchenko, Jeffrey M., Ansell, Stephen M., Bartlett, Nancy L., Blum, Kristie A., Cashen, Amanda F., Casulo, Carla, Friedberg, Jonathan W., Johnston, Patrick B., Kahl, Brad S., Leonard, John P., Link, Brian K., Lossos, Izidore S., Martin, Peter, Maurer, Matt J., Mehta-Shah, Neha, Reagan, Patrick M., Westin, Jason R., Koff, Jean L., and Flowers, Christopher R.

Published
2022
Full Text
View/download PDF

25. Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity.

Author

Moreno, Alberto, Manning, Kelly, Azeem, Maryam I., Nooka, Ajay K., Ellis, Madison, Manalo, Renee Julia, Switchenko, Jeffrey M., Wali, Bushra, Kaufman, Jonathan L., Hofmeister, Craig C., Joseph, Nisha S., Lonial, Sagar, Dhodapkar, Kavita M., Dhodapkar, Madhav V., and Suthar, Mehul S.

Abstract

Hematological malignancies are associated with an increased risk of complications during SARS-CoV-2 infections. Primary series or monovalent booster vaccines reduce disease severity, hospitalization, and death among multiple myeloma patients. We characterized virus-neutralizing and spike-binding antibody profiles following monovalent (WA1) or bivalent (WA1/BA.5) SARS-CoV-2 booster vaccination in MM patients. Bivalent vaccination improved the breadth of binding antibodies but not neutralization activity against contemporary variants. Hybrid immunity and immune imprinting impact vaccine-elicited immunity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Assessing survival outcomes of patients with oral tongue squamous cell carcinoma: Focus on age, sex, and stage.

Author

Pamulapati, Saagar, Abousaud, Marin, Li, Yixuan, Ekpenyong, Asari, Rudra, Soumon, Remick, Jill S., Bates, James E., Stokes, William A., McDonald, Mark W., Schmitt, Nicole C., El‐Deiry, Mark W., Patel, Mihir R., Steuer, Conor E., Switchenko, Jeffrey M., Shin, Dong M., Teng, Yong, Hammond, Anthea, and Saba, Nabil F.

Subjects
OVERALL survival, SQUAMOUS cell carcinoma, OLDER patients, SURVIVAL rate, DATABASES
Abstract

Background: The purpose of this study was to provide further insights into whether age and/or sex are associated with prognosis in oral tongue squamous cell carcinoma. Methods: This was a retrospective cohort study utilizing hospital registry data from 2006 to 2016 obtained from the National Cancer Database. Identified patients were divided into various cohorts based on age, sex, and staging. A descriptive analysis was performed using chi‐square tests and overall survival rates were estimated using Kaplan–Meier method. Results: A total of 17 642 patients were included in the study. The 5‐year overall survival rates were 82.0% (95% CI: 79.8%–84.0%) in younger patients versus 67.5% (95% CI: 66.7%–68.3%, p‐value <0.0001) older patients. The median overall survival for females was 143.4 months (95% CI: 133.2–NA) versus 129.8 (95% CI: 125.4–138.7, p‐value <0.0001) in males. Conclusions: Our analysis suggests that younger age and female sex are both predictors of improved survival in oral tongue squamous cell carcinoma. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study

Author

Qian, David C, Kleber, Troy, Brammer, Brianna, Xu, Karen M, Switchenko, Jeffrey M, Janopaul-Naylor, James R, Zhong, Jim, Yushak, Melinda L, Harvey, R Donald, Paulos, Chrystal M, Lawson, David H, Khan, Mohammad K, Kudchadkar, Ragini R, and Buchwald, Zachary S

Published
2021
Full Text
View/download PDF

30. Melanoma Cell Intrinsic GABAA Receptor Enhancement Potentiates Radiation and Immune Checkpoint Inhibitor Response by Promoting Direct and T Cell-Mediated Antitumor Activity

Author

Pomeranz Krummel, Daniel A., Nasti, Tahseen H., Kaluzova, Milota, Kallay, Laura, Bhattacharya, Debanjan, Melms, Johannes C., Izar, Benjamin, Xu, Maxwell, Burnham, Andre, Ahmed, Taukir, Li, Guanguan, Lawson, David, Kowalski, Jeanne, Cao, Yichun, Switchenko, Jeffrey M., Ionascu, Dan, Cook, James M., Medvedovic, Mario, Jenkins, Andrew, Khan, Mohammad K., and Sengupta, Soma

Published
2021
Full Text
View/download PDF

39. SAMHD1 expression contributes to doxorubicin resistance and predicts survival outcomes in diffuse large B-cell lymphoma patients

Author

Daddacha, Waaqo, primary, Monroe, Dominique, additional, Schlafstein, Ashley J, additional, Withers, Allison E, additional, Thompson, Elizabeth B, additional, Danelia, Diana, additional, Luong, Nho C, additional, Sesay, Fatmata, additional, Rath, Sandip K, additional, Usoro, Edidiong R, additional, Essien, Mark E, additional, Jung, Andrew T, additional, Jiang, Jinmeng G, additional, Hu, Jiaxuan, additional, Mahboubi, Bijan, additional, Williams, Arilyn, additional, Steinbeck, Julia E, additional, Yang, Xiaofeng, additional, Buchwald, Zachary S, additional, Dynan, William S, additional, Switchenko, Jeffrey M, additional, Kim, Baek, additional, Khan, Mohammad K, additional, Jaye, David L, additional, and Yu, David S, additional

Published
2024
Full Text
View/download PDF

44. Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative

Author

Gamboa, Adriana C., Zaidi, Mohammad Y., Lee, Rachel M., Speegle, Shelby, Switchenko, Jeffrey M., Lipscomb, Joseph, Cloyd, Jordan M., Ahmed, Ahmed, Grotz, Travis, Leiting, Jennifer, Fournier, Keith, Lee, Andrew J., Dineen, Sean, Powers, Benjamin D., Lowy, Andrew M., Kotha, Nikhil V., Clarke, Callisia, Gamblin, T. Clark, Patel, Sameer H., Lee, Tiffany C., Lambert, Laura, Hendrix, Ryan J., Abbott, Daniel E., Vande Walle, Kara, Lafaro, Kelly, Lee, Byrne, Johnston, Fabian M., Greer, Jonathan, Russell, Maria C., Staley, Charles A., and Maithel, Shishir K.

Published
2020
Full Text
View/download PDF

50. The importance of surgery in scalp angiosarcomas

Author

Cassidy, Richard J., Switchenko, Jeffrey M., Yushak, Melinda L., Madden, Nicholas, Khan, Mohammad K., Monson, David K., Beitler, Jonathan J., Landry, Jerome C., Godette, Karen D., Gillespie, Theresa W., and Patel, Kirtesh R.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results